Overall, these NGF panels demonstrate that incorporating B-cell markers such as CD22 and CD24 into existing panels, which traditionally rely on CD19 for the identification of (malignant) B-cells, enables reliable MRD assessment down to 0.001% in CD19-targeted BCP-ALL patients, if sufficient cells are required. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.